Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03742011 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Offspring Born to Mothers With Polycystic Ovary Syndrome in Guangzhou Cohort Study

Study acronym: PCOS-BIG
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 26, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 31, 2023 to Dec 31, 2025v6
  2. Re-verified, no change to tracked fieldsv5
  3. Primary completion date: Dec 31, 2020 to Dec 31, 2023v4
  4. Primary completion date: Dec 31, 2019 to Dec 31, 2020v3
  5. Secondary endpoints revised (12)v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The Offspring Born to Mothers with Polycystic Ovary Syndrome in Guangzhou Cohort study (PCOS-BIG) was established to investigate the short- and long-term effects of intrauterine exposure to maternal PCOS on the health of offspring in Guangzhou, China. Data are collected regarding maternal PCOS subtypes, nursing, diet and education as well as health outcomes in their later life. Biological samples including blood and tissue samples are also collected from participants.
Trial Details
NCT Number NCT03742011
Lead Sponsor Guangzhou Women and Children's Medical Center
Collaborators: University of Birmingham
Conditions
(from sponsor)		 PCOS, Offspring, Adult, Hyperandrogenism, Epigenetics, Insulin Resistance, Endocrine Disorder, Metabolic Disturbance
Related terms Endocrine System Diseases, Hyperandrogenism, Insulin Resistance
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov